Barclays upgraded Vertex Pharmaceuticals (NASDAQ: VRTX) from Equal-Weight to Overweight, indicating a positive outlook on the stock.Barlow Wealth Partners Inc. reduced its stake in Vertex by 41.4%, selling 21,078 shares, while Brighton Jones LLC and ORG Partners LLC increased their holdings, showing mixed investor sentiment.The current stock price of Vertex is $474.17, with a market capitalization of approximately $121.57 billion, reflecting its significant position in the biotech sector.Vertex Pharmaceutic ...